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Case report:
Multifocal primary tumour with lesions in prostate gland and urinary bladder: clinical case
Romaniuk A1, Lyndin M2, Sikora V3, Piddubnyi A4, Budko H5, Volkogon A6 
Abstract
In	some	cases	a	combination	of	several	malignant	tumours	in	one	person	can	be	observed.	In	
such	case	it	is	the	multifocal	primary	tumour	(MPT).	The	tumours	combination	in	genitourinary	
system	 is	 rare	 phenomenon,	 including	 a	 rare	 combination	 of	 prostate	 and	 urinary	 bladder	
cancers.	These	pathologies	can	be	caused	by	both	the	endogenous	factors	-	age,	gender,	heredity,	
inflammatory	 and	 proliferative	 processes,	 abnormal	 inclusions	 (calculi	 and	 amyloids)	 and	
exogenous	factors,	among	which	the	leading	cause	is	the	environmental	pollution	(heavy	metals	
salts	and	others),	bad	habits,	occupational	hazards,	oncogenic	viruses	and	ionizing	radiation.
A	76	-	year-	old	male	patient,	Ukrainian,	was	hospitalized	at	urology	department	with	complaints	
on	pollakiuria,	frequent	urinary	retention,	haematuria appeared	about	1	month	before.
After	 examination	 of	 patient	 the	 preliminary	 diagnosis	was	made:	 «Urinary	 bladder	 cancer,	
acute	urinary	retention,	macrohematuria	and	posthemorrhagic	anemia».	
Based	 on	 the	 histological	 and	 immunohistochemical	 examinations,	 the	 final	 diagnosis	 was	
determined:	combined	malignant	tumours	-	acinar	adenocarcinoma	of	prostate	index	9	(5	+	4)	
accordimg to D.F. Gleason and invasive urothelial carcinoma of the urinary bladder.
This	clinical	case	demonstrates	 that	 the	probability	of	combined	oncologic	cancer	pathology	
with	lesions	in	one	system	is	rather	high.	Therefore,	in	order	to	exclude	the	cancer	combinations,	
the	 patients	 with	malignant	 tumour	 in	 the	 genitourinary	 system	 should	 undergo	 a	 complex	
examination. 
Keywords: Cancer;	 prostate;	 urinary	 bladder;	 multifocal	 primary	 tumour;	 case	 report;	
immunohistochemical examination.
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Introduction.
Urinary	 bladder	 cancer	 (UBC)	 is	 highly	 ranked	
among	 oncologic	 pathologies	 and	 accounts	 up	 to	
3.3%	 of	 all	 malignant	 tumours.	 And	 this	 figure	
increases annually1.	In	Europe	it	is	the	fifth	common	
cancer	in	male	–	14.4	cases	per	100	000	population	
(mortality rate - 4.5). 5-year survival in non-invasive 
UBC	is	96%,	but	it	is	sharply	reduced	to	70%	if	the	
tumour	 spreads	 through	 the	 organ	 and	 up	 to	 5.5%	
with	the	presence	of	distant	metastases	2,3.
Prostate cancer (PC) is a tumour that is more common 
in	men	aged	over	70	years.	In	Europe	the	incidence	of	
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prostate	cancer	is	96.0	cases	per	100	000	population	
(mortality	rate	-	19.3)	that	constantly	increases	3,4. As 
the diagnosis and treatment methods are constantly 
improved,	 the	 5-year	 survival	 of	 patients	 with	
prostate	and	urinary	bladder	cancers	has	increased5. 
In	 most	 cases	 the	 prostate	 and	 urinary	 bladder	
cancers can be diagnosed by clinical, laboratory 
and instrumental examinations6,7.	Depending	on	 the	
stage of the disease, tumour dissemination, grade of 
differentiation	and	immunophenotype,	the	treatment	
of	 prostate	 and	 urinary	 bladder	 cancer	 is	 carried	
out	 by	 surgical	 procedures	 (transurethral	 resection,	
cystectomy,	prostatectomy,	etc.),	polychemotherapy,	
immunotherapy,	 hormonal	 treatment,	 radiotherapy	
and	symptomatic	treatment	5,8.
In some cases a combination of several malignant 
tumours	in	one	person	can	be	observed.	In	such	case	
it	is	the	multifocal	primary	tumour	(MPT).	Although	
the lesions of both organs are observed, the survival 
of	patients	is	higher	compared	with	patients	with	one	
tumour,	due	to	the	presence	of	differentiated	tumours	
in	 patients	 with	 MPT9.	 The	 tumours	 combination	
in	 genitourinary	 system	 is	 rare	 phenomenon	 10, 
including	a	rare	combination	of	prostate	and	urinary	
bladder cancers 6.	These	pathologies	can	be	caused	
by both the endogenous factors - age, gender, 
heredity,	 inflammatory	 and	 proliferative	 processes,	
abnormal inclusions (calculi and amyloids) and 
exogenous	factors,	among	which	the	leading	cause	is	
the	environmental	pollution	(heavy	metals	salts	and	
others),	bad	habits,	occupational	hazards,	oncogenic	
viruses and ionizing radiation 6,11-14.
Case presentation
A	 76	 -	 year-	 old	 male	 patient,	 Ukrainian,	 was	
hospitalized	at	urology	department	with	complaints	
on	pollakiuria,	frequent	urinary	retention,	haematuria 
(blood	in	the	urine)	appeared	about	1	month	before.
During	 examination	 the	 anemia	 was	 revealed,	 the	
erythrocyte	 sedimentation	 rate	 was	 increased	 and	
macrohematuria	was	present.	The	pelvic	ultrasound	
revealed	the	tumour	on	the	back	wall	of	the	urinary	
bladder,	which	invades	in	all	its	layers.	The	cystoscopy	
revealed	 the	 round	 mass	 on	 the	 back	 wall	 of	 the	
urinary	 bladder	 that	 was	 5.0	 cm	 in	 diameter,	 pink	
colored	 and	 tightly	 adjoined	 to	 the	 urinary	 bladder	
neck.	Erosions	were	present	on	the	surface	of	tumour,	
bleeding	at	the	touch.	After	examination	of	patient	the	
preliminary	 diagnosis	 was	made:	 «Urinary	 bladder	
cancer, acute urinary retention, macrohematuria and 
posthemorrhagic	 anemia».	 Preoperative	 treatment	
was	 determined:	 detoxification	 (saline,	 Ringer’s	
solution),	antibiotics,	analgesics	and	spasmolytics.
By	transurethral	resection,	the	tumour	and	adjoining	
tissues	were	 removed.	The	 fragments	were	fixed	 in	
10%	formaldehyde	solution	and	sent	to	histological	
laboratory.	The	histological	examination	of	patterns,	
stained	 with	 hematoxylin	 and	 eosin	 revealed	 the	
tumour	 infiltrates	 in	 smooth	 muscle	 stroma.	 Most	
of	 them	 were	 round,	 irregular	 shaped	 complexes	
with	 cribriform	 and	 solid	 architecture	 of	 growth.	
In	 solid	 patterns,	 almost	 complete	 loss	 of	 glands	
lumen	 was	 observed.	 Tumour	 cells	 were	 atypical	
epithelial	complexes,	delineated	by	pale	eosinophilic	
cytoplasm,	 with	 moderately	 polymorphic	 rounded-
oval	 nuclei	 and	 significantly	 enlarged	 nucleoli	
(Figure	 2A).	 In smaller area of tumour tissue an 
adenocarcinoma	 was	 present	 with	 spreading	 small	
glands	 or	 chains	 and	 strands	 of	 epithelium	 that	
merged	 together	 and	 infiltrated	 the	 prostate	 gland	
tissue	 (PGT).	 In	most	 cases	 the	 infiltrate	 cells	 had	
large,	irregularly	shaped	nuclei	with	distinct	nucleoli,	
eosinophilic	or	amphiphilic	cytoplasm	was	around	in	
different ratio. In some tumour lesions the necrosis 
was	present.	The	changes	were	determined	as	acinar	
adenocarcinoma	of	high	grade	of	malignancy,	with	9	
(5	+	4)	index	according	to	D.F.	Gleason.
In	 other	 areas	 of	 specimens	 the	 diffuse	 infiltrates	
were	 revealed,	 consisting	 of	 rounded-oval	 cells,	
some	of	them	were spindle-shaped.	Tumor	cells	had	
nucleus	of	different	shapes	with	dispersed	and	rough-
dispersed	 chromatin	 without	 clear	 nucleoli	 (Figure	
2B).	Around	 the	nucleus	 there	was	moderately	 and	
low	expressed	eosinophilic	cytoplasm.	High	rate	of	
mitosis	was	observed	 in	 tumour	 cells	 (more	 than	5	
in	 5	 fields	 of	 view	 with	 microscope	 magnification	
- 400). In some areas the histologic features of 
tumour	were	similar	to	lymphoma	with	plasmacytic	
differentiation of cells (eccentrically located nuclei 
with	 densely	 eosinophilic	 cytoplasm).	The	 changes	
in	the	determined	part	of	the	tumour	were	defined	as	
undifferentiated	malignant	neoplasia.
To	 verify	 the	 diagnosis,	 the	 immunohistochemical	
study	was	carried	out.	Screening	panel	of	antibodies	
included	 cytokeratin	 pan	 (PCK),	 CD45	 (leukocyte	
common	antigen	 -	LCA)	 and	vimentin.	The	 results	
were	the	following:	both	types	of	malignant	tumours	
were	 positive	 for	 CK	 pan,	 but	 receptors	 LCA	 and	
vimentin	didn’t	expressed	(Figure	3).	
It	should	be	noted	that	vimentin-positive	cytoplasmic	
reaction	was	observed	in	stromal	sells	of	all	tumours	
and	 the	 positive	 membrane	 reaction	 on	 expression	
of LCA - in leucocytes, singly-scattered in tumour. 
Based	 on	 the	 results,	 the	 epithelial	 origin	 of	 both	
malignant	tumours	was	determined.
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Later	 the	 immunohistochemical	 study	 with	 other	
antibodies	was	 carried	 out:	 CK	LMW	 (8,	 18),	 CK	
HMW	(5,	 14),	CK	7	 and	CK	20.	The	 results	were	
the	 following:	 adenocarcinoma	 tissue	 had	 positive	
heterogeneous	reaction	on	CK	LMW,	it	was	the	CK	
HMW	«	-	»,	CK	7	«	-	»	and	CK	20	«	-	».	The	tissue	
of	undifferentiated	tumour	expressed	all	types	of	CK	
(Figure 4).
At the last stage of immunohistochemical study the 
identification	of	 specific	 receptors	 (androgen	 (AR),	
prostate-specific	 antigen	 (PSA)	 and	AMACR)	 was	
carried	out.	The	adenocarcinoma	tissue	had	a	distinct	
positive	 nuclear	 reaction	 on	 AR	 and	 cytoplasmic	
reaction	on	PSA	and	AMACR	receptors.	The	tissue	
of undifferentiated tumour had heterogeneous 
expression	on	AMACR	receptors	and	was	negative	
on	AR	and	PSA	receptors	(Figure	5).
Based on the histological and immunohistochemical 
studies,	the	final	diagnosis	was	determined:	combined	
malignant	tumours	-	acinar	adenocarcinoma	of	prostate	
index	9	(5	+	4)	accordimg	to	D.F.	Gleason	and	invasive 
urothelial carcinoma of the	urinary	bladder	(Table	1).
Table	1.	Immunohistochemical	characteristic	of	tumours.
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Medicinal	 postoperative	 treatment	 included the 
third-generation	cephalosporin	and	fluoroquinolones	
antibiotics,	analgesics	and	antiseptics.
Discussion
According	to	Warren	and	Gates	in	case	of	MPT	the	
probability	 that	a	 tumour	 is	a	metastasis	of	another	
one	 should	 be	 completely	 excluded	 [10.15].	Based	
on	the	clinical	picture	of	the	patient,	that	was	typical	
for	 malignant	 tumour	 of	 urinary	 bladder,	 the	 first	
diagnosis	was	urinary	bladder	cancer.	This	diagnosis	
was	 also	 confirmed	 by	 cystoscopy.	 During	 the	
surgery	 the	 part	 of	 prostate	 with	 adjoining	 tissues	
were	removed	and	together	with	the	urinary	bladder	
tumour	 tissues	were	 sent	 to	histological	 laboratory.	
The	 histological	 and	 immunohistochemical	 studies	
revealed the combined malignant tumour that 
emerged	 from	 transitional	 epithelium	 of	 urinary	
bladder	and	acinar	epithelium	of	prostate.
In	world	literature	there	are	some	cases	of	combined	
neoplastic	lesions	of	urinary	bladder,	prostate,	kidney,	
thyroid	 and	 others.	 [6,10,15].	 The	 combination	 of	
urinary	bladder	and	prostate	cancers	 is	 rather	often	
phenomenon	among	cases	of	MPT	of	genitourinary	
system.	If	one	of	these	malignant	tumours	is	present	
the	risk	of	pathologies	combination	increases	in	18-19	
times	[6,16,17].	The	risk	of	second	malignant	tumour	
is caused by general carcinogenic affect of substances, 
place	 of	 residence	 and	 work	 in	 environmentally	
polluted	 areas,	 genetic	 predisposition,	 a	 side	 effect	
of	 chemotherapy	 or	 radiation	 therapy	 [1,11,15,16].	
In given case, a combination of several factors is 
present:	 age,	 living	 on	 environmentally	 polluted	
territory	with	 a	 high	 content	 of	 heavy	metals	 salts	
and	chronic	smoking.
Due	to	the	fact	that	prostate	cancer	is	observed	in	a	
significant	number	of	patients	with	UBC	it	is	important	
to	make	a	blood	test	for	PSA	in	preoperative	period	
to	exclude	the	lesion	of	prostate	gland.	Moreover,	in	
postoperative	 period,	 the	 increased	 level	 of	 serous	
prostate-specific	antigen	up	to	22	ng	/	ml	(reference	
value	0-4	ng	/	ml)	was	revealed	that	can	be	considered	
as	 the	 result	 of	 prostate	 gland	 traumatizing	 during	
the	 surgery	 or	 influence	 of	malignant	 tumour.	 It	 is	
important	to	study	the	specimen	by	using	the	modern	
immunohistochemical	 and	 cytomorphological	
methods	 that	 finally	 determines	 the	 histogenesis	 of	
tumour	growth.
The	further	treatment	of	patient	should	be	adjusted;	
the	 prostatectomy,	 polychemotherapy,	 radiotherapy	
and	hormonal	treatment	should	be	carried	out.	Taking	
into account that the tumour didn’t invade into nearby 
organs	and	distant	metastasis	were	absent,	in	case	of	
appropriate	 treatment,	 the	 prognosis	 for	 the	 patient	
is	 relatively	 favorable.	This	 case	 report	 is	 ethically	
approved.
Conclusion
This	clinical	case	demonstrates	that	the	probability	of	
combined	 oncologic	 cancer	 pathology	with	 lesions	
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in	one	system	is	 rather	high.	Therefore,	 in	order	 to	
exclude	 the	 cancer	 combinations,	 the	 patients	with	
malignant tumour in the genitourinary system should 
undergo	a	complex	examination.	 If	 the	histological	
study didn’t reveal the tumour histogenesis, the 
additional examinations of tumour should be carried 
out, including immunohistochemical determination 
of	the	receptors	in	neoplastic	cells.
Conflictof intetrest: None
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